These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 37372997)

  • 1. Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.
    Berna-Rico E; Perez-Bootello J; Abbad-Jaime de Aragon C; Gonzalez-Cantero A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review.
    Wang CY; Wang CW; Chen CB; Chen WT; Chang YC; Hui RC; Chung WH
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.
    Vasilopoulos Y; Manolika M; Zafiriou E; Sarafidou T; Bagiatis V; Krüger-Krasagaki S; Tosca A; Patsatsi A; Sotiriadis D; Mamuris Z; Roussaki-Schulze A
    Mol Diagn Ther; 2012 Feb; 16(1):29-34. PubMed ID: 22111980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis.
    Indhumathi S; Rajappa M; Chandrashekar L; Ananthanarayanan PH; Thappa DM; Negi VS
    Eur J Clin Pharmacol; 2017 Aug; 73(8):965-971. PubMed ID: 28444425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
    Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
    Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics and the resulting impact on psoriasis therapies.
    Foulkes AC; Warren RB
    Dermatol Clin; 2015 Jan; 33(1):149-60. PubMed ID: 25412789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
    Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis.
    Membrive Jiménez C; Pérez Ramírez C; Sánchez Martín A; Vieira Maroun S; Arias Santiago SA; Ramírez Tortosa MDC; Jiménez Morales A
    J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33921427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis.
    Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
    Pharmacogenomics; 2015; 16(15):1723-31. PubMed ID: 26415694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How genetic variation affects patient response and outcome to therapy for psoriasis.
    Woolf RT; Smith CH
    Expert Rev Clin Immunol; 2010 Nov; 6(6):957-66. PubMed ID: 20979559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.
    Membrive-Jiménez C; Pérez-Ramírez C; Arias-Santiago S; Richetta AG; Ottini L; Pineda-Lancheros LE; Ramírez-Tortosa MDC; Jiménez-Morales A
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.
    Murdaca G; Negrini S; Magnani O; Penza E; Pellecchio M; Puppo F
    Expert Opin Drug Saf; 2017 Oct; 16(10):1173-1179. PubMed ID: 28750567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
    Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
    J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.
    Masouri S; Stefanaki I; Ntritsos G; Kypreou KP; Drakaki E; Evangelou E; Nicolaidou E; Stratigos AJ; Antoniou C
    Mol Diagn Ther; 2016 Jun; 20(3):221-5. PubMed ID: 27043841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
    Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
    Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.
    Ryan C; Kelleher J; Fagan MF; Rogers S; Collins P; Barker JN; Allen M; Hagan R; Renfro L; Kirby B
    Clin Exp Dermatol; 2014 Jun; 39(4):519-24. PubMed ID: 24758522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
    Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
    Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics Update on Biologic Therapy in Psoriasis.
    Muñoz-Aceituno E; Martos-Cabrera L; Ovejero-Benito MC; Reolid A; Abad-Santos F; Daudén E
    Medicina (Kaunas); 2020 Dec; 56(12):. PubMed ID: 33419370
    [No Abstract]   [Full Text] [Related]  

  • 19. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
    Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
    Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
    [No Abstract]   [Full Text] [Related]  

  • 20. FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.
    Mendrinou E; Patsatsi A; Zafiriou E; Papadopoulou D; Aggelou L; Sarri C; Mamuris Z; Kyriakou A; Sotiriadis D; Roussaki-Schulze A; Sarafidou T; Vasilopoulos Y
    Pharmacogenomics J; 2017 Jun; 17(3):237-241. PubMed ID: 27044681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.